DE69615399T2 - Triacetin zur erhöhung der transdermalen penetration - Google Patents
Triacetin zur erhöhung der transdermalen penetrationInfo
- Publication number
- DE69615399T2 DE69615399T2 DE69615399T DE69615399T DE69615399T2 DE 69615399 T2 DE69615399 T2 DE 69615399T2 DE 69615399 T DE69615399 T DE 69615399T DE 69615399 T DE69615399 T DE 69615399T DE 69615399 T2 DE69615399 T2 DE 69615399T2
- Authority
- DE
- Germany
- Prior art keywords
- triacetine
- transdermal penetration
- increasing transdermal
- increasing
- penetration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/429,757 US5601839A (en) | 1995-04-26 | 1995-04-26 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
PCT/US1996/004845 WO1996033678A1 (en) | 1995-04-26 | 1996-04-08 | Triacetin as a transdermal penetration enhancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69615399D1 DE69615399D1 (de) | 2001-10-25 |
DE69615399T2 true DE69615399T2 (de) | 2003-01-30 |
Family
ID=23704623
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200512000013 Pending DE122005000013I1 (de) | 1995-04-26 | 1996-04-08 | Triacetin zur Erhöhung der transdermalen Penetration. |
DE69615399T Expired - Lifetime DE69615399T2 (de) | 1995-04-26 | 1996-04-08 | Triacetin zur erhöhung der transdermalen penetration |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200512000013 Pending DE122005000013I1 (de) | 1995-04-26 | 1996-04-08 | Triacetin zur Erhöhung der transdermalen Penetration. |
Country Status (19)
Country | Link |
---|---|
US (2) | US5601839A (de) |
EP (1) | EP0871420B1 (de) |
JP (2) | JP3228341B2 (de) |
KR (1) | KR100275593B1 (de) |
CN (3) | CN1507918A (de) |
AR (1) | AR001721A1 (de) |
AT (1) | ATE205694T1 (de) |
AU (1) | AU696777B2 (de) |
CA (1) | CA2217888C (de) |
DE (2) | DE122005000013I1 (de) |
DK (1) | DK0871420T3 (de) |
ES (1) | ES2163012T3 (de) |
FR (1) | FR05C0008I2 (de) |
HK (1) | HK1084320A1 (de) |
NL (1) | NL300200I1 (de) |
NZ (1) | NZ306249A (de) |
PT (1) | PT871420E (de) |
WO (1) | WO1996033678A1 (de) |
ZA (1) | ZA963229B (de) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5633000A (en) * | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
AU3601897A (en) * | 1996-07-15 | 1998-02-09 | Alza Corporation | Novel formulations for the administration of fluoxetine |
US6572880B2 (en) | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US6290986B1 (en) | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
WO1998018416A1 (en) * | 1996-10-30 | 1998-05-07 | Theratech, Inc. | Fatty acid esters of glycolic acid and its salts as permeation enhancers |
US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
DE19706824C1 (de) * | 1997-02-21 | 1998-03-26 | Lohmann Therapie Syst Lts | Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften |
US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US6319913B1 (en) * | 1997-11-10 | 2001-11-20 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
TW492882B (en) * | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
US20020102291A1 (en) * | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
EP1459741A1 (de) * | 1997-12-15 | 2004-09-22 | Noven Pharmaceuticals, Inc. | Arzneimittel und Verfahren zur Behandlung von Aufmerksamkeitsstörungen und Aufmerksamkeits-/hyperaktivitätsstörungen mit Methylphenidat |
US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US6727401B1 (en) * | 1998-02-12 | 2004-04-27 | Watson Pharmaceuticals, Inc. | Pressure sensitive adhesive matrix patch for the treatment of onychomycosis |
DE29823343U1 (de) | 1998-03-20 | 1999-07-15 | Sanol Arznei Schwarz Gmbh | Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend |
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
US6475514B1 (en) | 1998-12-03 | 2002-11-05 | Andrew Blitzer | Athletic patch |
KR100383252B1 (ko) * | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
AU3536799A (en) * | 1999-04-26 | 2000-11-10 | Lead Chemical Co., Ltd. | Percutaneous preparations containing oxybutynin |
WO2000076490A2 (en) * | 1999-06-10 | 2000-12-21 | Sepracor Inc. | Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin |
NZ516765A (en) | 1999-06-25 | 2003-04-29 | Durham Pharmaceuticals Ltd | Topical formulations comprising skin penetration agents and the use thereof |
GB9918735D0 (en) * | 1999-08-09 | 1999-10-13 | Straken Limited | Transdermal patches |
US20010049546A1 (en) * | 2000-02-08 | 2001-12-06 | Israel Dvoretzky | Multi-purpose drug and heat therapy treatment system |
US6436428B1 (en) | 2000-03-21 | 2002-08-20 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
CN1438861A (zh) * | 2000-04-26 | 2003-08-27 | 沃特森药物公司 | 最小化与奥昔布宁疗法有关的副作用 |
US7029694B2 (en) * | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7214381B2 (en) * | 2000-08-03 | 2007-05-08 | Antares Pharma Ipl Ag | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10060550C1 (de) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
US6585963B1 (en) * | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
EP1390383B1 (de) * | 2001-05-11 | 2012-02-29 | Isis Pharmaceuticals, Inc. | Antisense-permeationsverstärker |
US6913760B2 (en) * | 2001-08-06 | 2005-07-05 | New England Medical Hospitals, Inc. | Drug delivery composition |
AU2002340120A1 (en) * | 2001-10-04 | 2003-04-14 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
US7921999B1 (en) * | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
JP4295467B2 (ja) * | 2002-04-12 | 2009-07-15 | 日東電工株式会社 | 貼付剤およびその製造方法 |
KR100469995B1 (ko) * | 2002-05-20 | 2005-02-05 | 안국약품 주식회사 | 천식치료제를 함유한 매트릭스형 패취 |
JP4323138B2 (ja) * | 2002-06-05 | 2009-09-02 | 日東電工株式会社 | 経皮吸収型製剤およびその製造方法 |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
EP1386604A1 (de) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Verbessertes transdermales Verabreichungssystem |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
AU2003268361A1 (en) * | 2002-08-30 | 2004-03-19 | Watson Pharmaceuticals, Inc. | Drug delivery system for treating urinary incontinence |
DE10251256A1 (de) * | 2002-11-04 | 2004-05-13 | Novosis Ag | Transdermales Wirkstoffabgabesystem für Oxybutynin |
SI1426049T1 (en) * | 2002-12-02 | 2005-08-31 | Sanol Arznei Schwarz Gmbh | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
EP1620060B1 (de) * | 2003-04-29 | 2010-03-24 | The General Hospital Corporation | Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln |
DE10338174A1 (de) * | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
MXPA06003316A (es) | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Formulacion farmaceutica transdermica para minimizar los residuos en la piel. |
WO2005077364A1 (ja) * | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | ソリフェナシンの経皮投与製剤およびその経皮透過改善方法 |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
EP1611882B1 (de) * | 2004-06-01 | 2010-04-07 | Hisamitsu Pharmaceutical Co., Inc. | Adhäsive Pflaster |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
JP5254616B2 (ja) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | 生物学的同調性(biosynchronous)経皮的薬物送達 |
US8252319B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
ATE551995T1 (de) | 2004-10-21 | 2012-04-15 | Durect Corp | Transdermale abgabesysteme |
US20070053965A1 (en) * | 2005-02-25 | 2007-03-08 | Gruenenthal Gmbh | Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation |
WO2007124250A2 (en) * | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
JP5037831B2 (ja) * | 2006-02-15 | 2012-10-03 | 久光製薬株式会社 | 凝集力向上及び徐放化の外用貼付剤 |
WO2007100757A2 (en) * | 2006-02-27 | 2007-09-07 | Noven Pharmaceuticals, Inc. | Transdermal therapeutic system comprising scopolamine |
WO2007143676A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
WO2007143674A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
US8889155B2 (en) * | 2006-12-28 | 2014-11-18 | Kaken Pharmaceutical Co., Ltd. | Gel composition for treating mycosis |
NZ552816A (en) * | 2007-01-24 | 2009-05-31 | Bomac Research Ltd | Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof |
KR101521989B1 (ko) | 2007-03-02 | 2015-05-28 | 테이카 세이야쿠 가부시키가이샤 | 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제 |
US20080226698A1 (en) * | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
US10183001B1 (en) * | 2007-05-22 | 2019-01-22 | Pisgah Laboratories, Inc. | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features |
EP2182987A4 (de) * | 2007-07-30 | 2011-11-02 | Medacure International Inc | Formulierung für immunsystemmodulator |
US20090098191A1 (en) * | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
ATE543493T1 (de) * | 2007-12-12 | 2012-02-15 | Teikoku Seiyaku Kk | Loxoprofenhaltiges wässriges pflaster |
US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
US8404255B2 (en) * | 2008-07-29 | 2013-03-26 | Matt Gibson | System and method for transdermal drug delivery |
CN102209627B (zh) | 2008-10-02 | 2013-11-06 | 迈兰公司 | 多层粘合剂层压制品的制造方法 |
JP5155128B2 (ja) * | 2008-12-11 | 2013-02-27 | 日東電工株式会社 | メチルフェニデート貼付製剤 |
US8920392B2 (en) * | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
WO2011049038A1 (ja) * | 2009-10-21 | 2011-04-28 | 帝國製薬株式会社 | ドネペジル含有経皮吸収型製剤 |
TW201129397A (en) | 2009-12-15 | 2011-09-01 | Teikoku Seiyaku Kk | Dermal absorption agent comprising alkali anti-inflammatory analgesic agent |
JP5927506B2 (ja) | 2010-04-13 | 2016-06-01 | レルマダ セラピューティクス、インク. | 1−メチル−2’,6’−ピペコロキシリダイドの皮膚医薬組成物および使用方法 |
WO2011137054A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
FR2972923B1 (fr) * | 2011-03-25 | 2013-08-23 | Urgo Lab | Composition filmogene contenant un filtre solaire, son utilisation pour le traitement des cicatrices |
MX349572B (es) | 2011-05-10 | 2017-08-03 | Itochu Chemical Frontier Corp | Parche no acuoso. |
US9925264B2 (en) | 2011-05-10 | 2018-03-27 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
WO2012174731A1 (en) * | 2011-06-24 | 2012-12-27 | Cheng Haiyung | Method and improved pharmaceutical composition for improving the absorption of an ester prodrug |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
EP3363432B1 (de) | 2011-09-27 | 2020-12-23 | Itochu Chemical Frontier Corporation | Nichtwässriges pflaster |
JP5462421B2 (ja) * | 2011-10-26 | 2014-04-02 | 久光製薬株式会社 | オキシブチニン含有経皮吸収製剤 |
US20130266643A1 (en) * | 2012-04-10 | 2013-10-10 | Hpo Life Sciences, Inc. | Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis |
KR102127625B1 (ko) * | 2012-09-03 | 2020-06-29 | 다이이찌 산쿄 가부시키가이샤 | 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물 |
AU2013318338B2 (en) | 2012-09-21 | 2017-05-25 | Intensity Therapeutics, Inc | Method of treating cancer |
US9072682B2 (en) | 2012-12-31 | 2015-07-07 | Mylan Inc. | Transdermal dosage form for low-melting point active agent |
CN103919754B (zh) * | 2013-01-15 | 2018-11-06 | 江苏康倍得药业股份有限公司 | 奥昔布宁药物组合物及其应用 |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
WO2014159573A1 (en) * | 2013-03-14 | 2014-10-02 | Noven Pharmaceuticals, Inc | Methylphenidate transdermal compositions with rubber-based adhesives |
US20170217976A1 (en) * | 2014-03-21 | 2017-08-03 | Chironwells Gmbh | 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament |
CA2973372A1 (en) | 2015-01-09 | 2016-07-14 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 薬剤送達方法及びシステム |
WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
EP3565617A1 (de) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Vorrichtungen und verfahren zur transdermalen wirkstofffreisetzung |
JP2019034905A (ja) * | 2017-08-17 | 2019-03-07 | コスメディ製薬株式会社 | デヒドロ酢酸含有経皮吸収製剤 |
WO2019089523A1 (en) * | 2017-10-30 | 2019-05-09 | Theracaine Llc | Hydrophobic acid addition salts and pharmaceutical formulations thereof |
KR101975677B1 (ko) | 2017-11-20 | 2019-05-07 | 양진석 | 환편기용 보풀 제거장치 |
CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
WO2020085879A1 (ko) | 2018-10-26 | 2020-04-30 | 경상대학교산학협력단 | 아세틴 화합물의 생물학적 제조 방법 |
CN113384558A (zh) * | 2021-02-01 | 2021-09-14 | 深圳普洛美康材料有限公司 | 一种递送大麻活性物质的透皮贴剂 |
JP2022122784A (ja) | 2021-02-10 | 2022-08-23 | コスメディ製薬株式会社 | 酸化防止剤含有経皮吸収製剤 |
KR20230026232A (ko) | 2021-08-17 | 2023-02-24 | 신신제약 주식회사 | 옥시부티닌을 함유하는 경피흡수제제 |
CN113749968A (zh) * | 2021-10-26 | 2021-12-07 | 奥易生物科技(杭州)有限公司 | 一种快速透皮吸收的化妆品及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US466926A (en) * | 1892-01-12 | Advertising device | ||
US4336262A (en) * | 1973-02-23 | 1982-06-22 | Fisons Ltd. | Pour-on veterinary anthelmintic |
EP0190262B1 (de) * | 1984-07-24 | 1990-12-27 | Key Pharmaceuticals, Inc. | Klebende schicht zur transdermalen freigabe |
US4895727A (en) * | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
US4666926A (en) * | 1986-02-27 | 1987-05-19 | Warner-Lambert Company | Transdermal formulations |
US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
JPH0676327B2 (ja) * | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイド軟膏製剤 |
US4857313A (en) * | 1987-05-28 | 1989-08-15 | Warner-Lambert Company | Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate |
US4879297A (en) * | 1987-06-01 | 1989-11-07 | Warner-Lambert Company | Fatty acids and their small chain esters as penetration enhancers in aqueous systems |
US4789547A (en) * | 1987-06-17 | 1988-12-06 | Warner-Lambert Company | Transdermal matrix system |
US4814173A (en) * | 1987-09-08 | 1989-03-21 | Warner-Lambert Company | Silicone elastomer transdermal matrix system |
JP2526256B2 (ja) * | 1987-11-17 | 1996-08-21 | 清水建設株式会社 | 構造物の振動抑制装置 |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
DE3943519A1 (de) * | 1989-04-27 | 1991-01-17 | Stief Georg | Arzneimittel zur behandlung erektiler dysfunktionen |
US5496819A (en) * | 1991-11-15 | 1996-03-05 | Ss Pharmaceutical Co., Ltd. | Antiphlogistic-analgesic plaster comprising triacetin and piroxicam |
JP3130350B2 (ja) * | 1991-11-28 | 2001-01-31 | 積水化学工業株式会社 | 経皮吸収製剤 |
TW224048B (de) * | 1992-03-30 | 1994-05-21 | Hoechst Roussel Pharma | |
ATE184473T1 (de) * | 1992-06-11 | 1999-10-15 | Theratech Inc | Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung |
JPH08245377A (ja) * | 1995-03-15 | 1996-09-24 | Yamanouchi Pharmaceut Co Ltd | 経皮吸収用製剤 |
JPH09309783A (ja) * | 1996-05-20 | 1997-12-02 | Chisso Corp | 改良された土中崩壊型被覆粒状肥料 |
-
1995
- 1995-04-26 US US08/429,757 patent/US5601839A/en not_active Expired - Lifetime
-
1996
- 1996-04-08 EP EP96911647A patent/EP0871420B1/de not_active Expired - Lifetime
- 1996-04-08 WO PCT/US1996/004845 patent/WO1996033678A1/en active IP Right Grant
- 1996-04-08 AT AT96911647T patent/ATE205694T1/de active
- 1996-04-08 CA CA002217888A patent/CA2217888C/en not_active Expired - Lifetime
- 1996-04-08 NZ NZ306249A patent/NZ306249A/xx not_active IP Right Cessation
- 1996-04-08 DK DK96911647T patent/DK0871420T3/da active
- 1996-04-08 JP JP53255096A patent/JP3228341B2/ja not_active Expired - Lifetime
- 1996-04-08 PT PT96911647T patent/PT871420E/pt unknown
- 1996-04-08 DE DE200512000013 patent/DE122005000013I1/de active Pending
- 1996-04-08 ES ES96911647T patent/ES2163012T3/es not_active Expired - Lifetime
- 1996-04-08 CN CNA2004100392112A patent/CN1507918A/zh active Pending
- 1996-04-08 CN CNB961934565A patent/CN1143688C/zh not_active Expired - Lifetime
- 1996-04-08 CN CNB2005100719966A patent/CN100374161C/zh not_active Expired - Lifetime
- 1996-04-08 KR KR1019970707309A patent/KR100275593B1/ko not_active IP Right Cessation
- 1996-04-08 AU AU54467/96A patent/AU696777B2/en not_active Expired
- 1996-04-08 DE DE69615399T patent/DE69615399T2/de not_active Expired - Lifetime
- 1996-04-23 ZA ZA963229A patent/ZA963229B/xx unknown
- 1996-04-26 AR AR33630496A patent/AR001721A1/es active IP Right Grant
-
1997
- 1997-01-03 US US08/775,367 patent/US5834010A/en not_active Expired - Lifetime
-
2000
- 2000-07-04 JP JP2000201747A patent/JP4511691B2/ja not_active Expired - Lifetime
-
2004
- 2004-12-21 NL NL300200C patent/NL300200I1/nl unknown
-
2005
- 2005-03-17 FR FR05C0008C patent/FR05C0008I2/fr active Active
-
2006
- 2006-03-04 HK HK06102837A patent/HK1084320A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69615399D1 (de) | Triacetin zur erhöhung der transdermalen penetration | |
DE69838689D1 (de) | Verfahren zur Aktualisierung von Konten | |
DE69817839D1 (de) | Verfahren zur erhöhung der photosynthese | |
DE69818930D1 (de) | Verfahren zur Ausrichtung von Text an Audiosignalen | |
DE59909597D1 (de) | Verfahren zur kontrolle der insulinmedikation | |
DE69828664D1 (de) | Verfahren zur Lenkweg-Auswahl | |
DE69614080D1 (de) | Verfahren zur Sanierung von Böden | |
DE59306790D1 (de) | Verfahren zur Überprüfung von Lambdasonden | |
DE69605447T2 (de) | Verfahren und nichtlineares filter zur verminderung der gleichkanalstörung | |
DE69413221D1 (de) | Verfahren zur druckqualitätskontrolle | |
DE69332556D1 (de) | Verfahren zur Mehrfehlerkorrektur | |
DE59406145D1 (de) | Verfahren zur gewinnung von adsorptionsmaterial | |
DK199801279A (da) | Fremgangsmåde til belægning af medicinske kanyler | |
DE69831792D1 (de) | Verfahren zur digitalen unterschrift | |
DE69313315D1 (de) | Verfahren zur Kontrastkorrektur | |
DE59810602D1 (de) | Verfahren zur qualitätskontrolle | |
ATE204130T1 (de) | Verfahren zur insektenbekämpfung mit 1- phenylpyrazolen oder 1-heteroarylpyrazolen | |
DE69738717D1 (de) | Verfahren zur rekalzifizierung der zähne | |
DE69327551D1 (de) | Verfahren zur Programmausführung | |
DE69800673T2 (de) | Verfahren zum Prüfen von Zigaretten | |
DE69522100T2 (de) | Verfahren zur abdeckung | |
DE59709665D1 (de) | Verfahren zur Verzugskorrektur | |
DE59402474D1 (de) | Verfahren zur Lautsprechereinstellung | |
DE59501064D1 (de) | Verfahren zur Unterdrückung des Einflusses von Walzenexzentrizitäten | |
DE69524313T2 (de) | Gerät zur Anzeige von Biosignalen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R071 | Expiry of right |
Free format text: PRODUCT NAME: OXYBUTYNIN ODER EIN SAURES ZUSATZSALZ DAVON ALS BASISDROGE IN MATRIXPFLASTERN ZUR TRAN: EU EU/1/03/270/001-2 20040615 SDERMALEN VERABREICHUNG; NAT. REGISTRATION NO/DATE: EU/1/03/270/001-002 20040615; FIRST REGISTRATION Spc suppl protection certif: 122005000013 Filing date: 20050318 Expiry date: 20160409 Extension date: 20190615 |